Dossier
clinicaltrials
trial early
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Key claim: A phase 1/early-phase clinical study is evaluating the safety and tolerability of INCA035784, a novel investigational agent, in patients with myeloproliferative neoplasms.
Abstract
This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.
Why this matters
INCA035784 represents a new investigational entry into the MPN therapeutic pipeline, expanding the set of Incyte-sponsored novel agents (alongside INCB057643 and INCA036978) being evaluated beyond the JAK inhibitor backbone. Even without disclosed mechanism, tracking its early-phase safety profile is important for mapping the evolving landscape of next-generation MPN therapeutics.